337 related articles for article (PubMed ID: 11264346)
1. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
Martín J; LaBranche CC; González-Scarano F
J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
Wyatt R; Moore J; Accola M; Desjardin E; Robinson J; Sodroski J
J Virol; 1995 Sep; 69(9):5723-33. PubMed ID: 7543586
[TBL] [Abstract][Full Text] [Related]
3. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.
McKeating JA; Shotton C; Cordell J; Graham S; Balfe P; Sullivan N; Charles M; Page M; Bolmstedt A; Olofsson S
J Virol; 1993 Aug; 67(8):4932-44. PubMed ID: 7687306
[TBL] [Abstract][Full Text] [Related]
4. Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity.
LaCasse RA; Follis KE; Moudgil T; Trahey M; Binley JM; Planelles V; Zolla-Pazner S; Nunberg JH
J Virol; 1998 Mar; 72(3):2491-5. PubMed ID: 9499111
[TBL] [Abstract][Full Text] [Related]
5. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.
Trkola A; Dragic T; Arthos J; Binley JM; Olson WC; Allaway GP; Cheng-Mayer C; Robinson J; Maddon PJ; Moore JP
Nature; 1996 Nov; 384(6605):184-7. PubMed ID: 8906796
[TBL] [Abstract][Full Text] [Related]
6. Peptide ligands selected with CD4-induced epitopes on native dualtropic HIV-1 envelope proteins mimic extracellular coreceptor domains and bind to HIV-1 gp120 independently of coreceptor usage.
Dervillez X; Klaukien V; Dürr R; Koch J; Kreutz A; Haarmann T; Stoll M; Lee D; Carlomagno T; Schnierle B; Möbius K; Königs C; Griesinger C; Dietrich U
J Virol; 2010 Oct; 84(19):10131-8. PubMed ID: 20660187
[TBL] [Abstract][Full Text] [Related]
7. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains.
Moore JP; Sattentau QJ; Yoshiyama H; Thali M; Charles M; Sullivan N; Poon SW; Fung MS; Traincard F; Pinkus M
J Virol; 1993 Oct; 67(10):6136-51. PubMed ID: 7690418
[TBL] [Abstract][Full Text] [Related]
8. Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction.
McKeating JA; Thali M; Furman C; Karwowska S; Gorny MK; Cordell J; Zolla-Pazner S; Sodroski J; Weiss RA
Virology; 1992 Sep; 190(1):134-42. PubMed ID: 1382339
[TBL] [Abstract][Full Text] [Related]
9. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates.
Lagenaur LA; Villarroel VA; Bundoc V; Dey B; Berger EA
Retrovirology; 2010 Feb; 7():11. PubMed ID: 20158904
[TBL] [Abstract][Full Text] [Related]
10. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region.
Wyatt R; Thali M; Tilley S; Pinter A; Posner M; Ho D; Robinson J; Sodroski J
J Virol; 1992 Dec; 66(12):6997-7004. PubMed ID: 1279195
[TBL] [Abstract][Full Text] [Related]
11. Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120.
Salzwedel K; Smith ED; Dey B; Berger EA
J Virol; 2000 Jan; 74(1):326-33. PubMed ID: 10590121
[TBL] [Abstract][Full Text] [Related]
12. Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4.
Gram GJ; Hemming A; Bolmstedt A; Jansson B; Olofsson S; Akerblom L; Nielsen JO; Hansen JE
Arch Virol; 1994; 139(3-4):253-61. PubMed ID: 7832633
[TBL] [Abstract][Full Text] [Related]
13. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.
Moore JP; Cao Y; Qing L; Sattentau QJ; Pyati J; Koduri R; Robinson J; Barbas CF; Burton DR; Ho DD
J Virol; 1995 Jan; 69(1):101-9. PubMed ID: 7527081
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization.
Grimaila RJ; Fuller BA; Rennert PD; Nelson MB; Hammarskjöld ML; Potts B; Murray M; Putney SD; Gray G
J Virol; 1992 Apr; 66(4):1875-83. PubMed ID: 1548744
[TBL] [Abstract][Full Text] [Related]
15. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change.
Thali M; Charles M; Furman C; Cavacini L; Posner M; Robinson J; Sodroski J
J Virol; 1994 Feb; 68(2):674-80. PubMed ID: 7507184
[TBL] [Abstract][Full Text] [Related]
16. Structure of a V3-containing HIV-1 gp120 core.
Huang CC; Tang M; Zhang MY; Majeed S; Montabana E; Stanfield RL; Dimitrov DS; Korber B; Sodroski J; Wilson IA; Wyatt R; Kwong PD
Science; 2005 Nov; 310(5750):1025-8. PubMed ID: 16284180
[TBL] [Abstract][Full Text] [Related]
17. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera.
Wrin T; Loh TP; Vennari JC; Schuitemaker H; Nunberg JH
J Virol; 1995 Jan; 69(1):39-48. PubMed ID: 7983734
[TBL] [Abstract][Full Text] [Related]
18. Phorbol ester-induced down modulation of tailless CD4 receptors requires prior binding of gp120 and suggests a role for accessory molecules.
Golding H; Dimitrov DS; Manischewitz J; Broder CC; Robinson J; Fabian S; Littman DR; Lapham CK
J Virol; 1995 Oct; 69(10):6140-8. PubMed ID: 7545243
[TBL] [Abstract][Full Text] [Related]
19. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions.
Binley JM; Cayanan CS; Wiley C; Schülke N; Olson WC; Burton DR
J Virol; 2003 May; 77(10):5678-84. PubMed ID: 12719560
[TBL] [Abstract][Full Text] [Related]
20. Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120.
McKeating JA; Bennett J; Zolla-Pazner S; Schutten M; Ashelford S; Brown AL; Balfe P
J Virol; 1993 Sep; 67(9):5216-25. PubMed ID: 7688820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
